8 Papers
11 Citations
Tara Berman is an academic researcher from Mount Sinai St. Luke's and Mount Sinai Roosevelt. The author has contributed to research in topics: Medicine & Ovarian cancer. The author has an hindex of 5, co-authored 7 publications. Previous affiliations of Tara Berman include Memorial Sloan Kettering Cancer Center & Tel Aviv Sourasky Medical Center.
Chat about Author
Papers
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
Vasilena Gocheva,Hao-Wei Wang,Bedrick B. Gadea,Tanaya Shree,Karen E. Hunter,Alfred L. Garfall,Tara Berman,Johanna A. Joyce +7 more
TL;DR: It is demonstrated that high levels of cathepsin protease activity are induced in the majority of macrophages in the microenvironment of pancreatic islet cancers, mammary tumors, and lung metastases during malignant progression and that interleukin-4 (IL-4) is responsible for inducing cat hepsin activity in macrophage in vitro and in vivo.
Human papillomavirus in cervical cancer and oropharyngeal cancer: One cause, two diseases
Tara Berman,John T. Schiller +1 more
TL;DR: Despite the common etiologic role of HPV in the development of cervical cancer and HPV‐associated OPC, great disparity exists between incidence, screening modalities, treatment, and prevention in these 2 very distinct cohorts.
358
BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups
T. Safra,T. Safra,W. C. Lai,L. Borgato,M. O. Nicoletto,Tara Berman,Elsa Reich,M. Alvear,Izhak Haviv,Izhak Haviv,Franco M. Muggia +10 more
TL;DR: It is confirmed that EOC BRCA mutation carriers have better prognosis with longer median survival than patients with nonhereditary disease, and the contribution of unclassified BRCa variants to cancer etiology remains undetermined.
30
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Tamar Safra,Tara Berman,Adelya Yachnin,Ilan Bruchim,Mihai Meirovitz,Frida Barak,Ilan Atlas,Tally Levy,Ora Solange Rosengarten,Ora Solange Rosengarten +9 more
TL;DR: In this large cohort of recurrent EOC, PPC, and tubal cancer, weekly topotecan was well tolerated with good clinical benefit rate, comparable to previous studies.
11
BRCA mutations and outcome in epithelial ovarian cancer (EOC): Experience in ethnically diverse groups.
Tamar Safra,Wei-Chu V Lai,Tara Berman,Lucia Borgato,Elsa Reich,Maria Alvear,Franco M. Muggia,Sharon Pelles-Avraham +7 more
TL;DR: A retrospective chart review of patients diagnosed with Stage IC-IV EOC between 1995-2008 at the NYU Cancer Institute, Tel Aviv Sourasky MC and Padova Clinical Cancer Centers finds that carrier frequency in EOC population is 46% (45/97) in AJ's and 48% (41/86) in non-AJ's.
5